| Atrophy (14) |  |
| Bleeding (66) | |
| Chest pain (4) | |
| Disability (104) | |
| Dystrophy (3) | |
| Edema (3) | |
| Fever (40) | |
| Fibrosis (56) | |
| Headache (11) | |
| Hyperplasia (4) | |
| Hypertrophy (3) | |
| Malignancy (12) | |
| Preeclampsia (11) | |
| Sclerosis (17) | |
| Sickness (10) | |
| Ulcer (28) | |
| Atrophy (14) | |
| Bleeding (66) | |
| Chest pain (4) | |
| Disability (104) | |
| Dystrophy (3) | |
| Edema (3) | |
| Fever (40) | |
| Fibrosis (56) | |
| Headache (11) | |
| Hyperplasia (4) | |
| Hypertrophy (3) | |
| Malignancy (12) | |
| Preeclampsia (11) | |
| Sclerosis (17) | |
| Sickness (10) | |
| Ulcer (28) | |
ranging from cardiac hypertrophy to neuropathic pain. The compound looks quite powerful for a number of conditions.
myobundles undergo dose-dependent hypertrophy or toxic myopathy similar to clinical outcomes. Human myobundles provide an enabling platform for predictive drug
and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor), "builds on recent research by the same team that previously identified a fat-and-sugar molecule called GSL as the chief culprit behind a range of biological glitches that affect the body's ability to properly use, transport
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011